Author

J. K. Ochieng

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

A. Padhye· 1 shared B. L. Rodriguez· 1 shared C. A. Class· 1 shared D. H. Peng· 1 shared D. L. Gibbons· 1 shared J. J. Fradette· 1 shared J. Wang· 1 shared L. A. Byers· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Padhye

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

D. H. Peng, B. L. Rodriguez, L. Diao, P. O. Gaudreau, A. Padhye, J. K. Ochieng, C. A. Class, J. J. Fradette, L. A. Gibson, L. Chen, J. Wang, L. A. Byers, D. L. Gibbons

This study shows that Th17 cells contribute to resistance to MEK inhibitor and anti-PD-L1 therapy in KRAS/p53 mutant lung cancers and suggests a triple combinatorial therapy to overcome resistance.

bioRxiv · Jun 7, 2020Cancer Biology